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Abstract
Objectives: To develop a new interface for the widely used prognostic breast can-
cer tool: Predict: Breast Cancer. To facilitate decision- making around post- surgery 
breast cancer treatments. To derive recommendations for communicating the outputs 
of prognostic models to patients and their clinicians.
Method: We employed a user- centred design process comprised of background re-
search and iterative testing of prototypes with clinicians and patients. Methods in-
cluded surveys, focus groups and usability testing.
Results: The updated interface now caters to the needs of a wider audience through 
the addition of new visualisations, instantaneous updating of results, enhanced ex-
planatory information and the addition of new predictors and outputs. A programme 
of future research was identified and is now underway, including the provision of 
quantitative data on the adverse effects of adjuvant breast cancer treatments.
Based on our user- centred design process, we identify six recommendations for com-
municating the outputs of prognostic models including the need to contextualise 
statistics, identify and address gaps in knowledge, and the critical importance of en-
gaging with prospective users when designing communications.
Conclusions: For prognostic algorithms to fulfil their potential to assist with decision- 
making they need carefully designed interfaces. User- centred design puts patients and 
clinicians needs at the forefront, allowing them to derive the maximum benefit from 
prognostic models.
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1 |  INTRODUCTION
Around 55,000 women are diagnosed with invasive breast 
cancer each year in the United Kingdom,1 with an estimated 
2  million new cases each year worldwide.2 These women, 
along with their healthcare professionals, need to make po-
tentially life- altering decisions about their treatment. In order 
to inform those decisions, they need comprehensible and bal-
anced information about the potential risks and benefits of 
the different treatment options.3
In 2010,4 a prognostic model called PREDICT was devel-
oped to estimate the survival benefits of different adjuvant 
(post- surgery) therapies for breast cancer. Individualised es-
timates are made on the basis of inputs describing the patient 
and their cancer. The PREDICT algorithm was embedded 
into a publicly available website, Predict: Breast Cancer, de-
signed primarily for clinicians.
Whilst the PREDICT statistical model has been exten-
sively validated,5– 10 the initial interface that allowed public 
access had not been designed or tested for comprehension 
and usability. It is well recognised that the ways in which 
numbers and evidence are presented can have a large impact 
on the audience's perception of risks and benefits, and on 
decisions made as a result.11 Careful design of the outputs 
of risk prediction algorithms is, therefore, necessary. Good 
design should improve comprehension, shared decision- 
making and standardisation of treatment. We, therefore, set 
out to redesign the Predict: Breast Cancer interface, using the 
principles of user- centred design (UCD),12 combined with 
knowledge from the literature on the visual communication 
of risk.11,13 This process resulted in a new interface collabo-
ratively developed with patients and clinicians.
The UCD process is widely used in industry and con-
sidered best practice when designing interactive systems. 
The use of UCD in a medical context is less common but 
increasingly recognised as important.14– 16 We outline how 
we applied the UCD process to the Predict: Breast Cancer 
interface, and develop recommendations that may help oth-
ers ensure prognostic models maximise their potential to help 
with decision- making.
Post- redesign, the site is delivering over 30,000 sessions 
per month. It is recommended by the National Institute for 
Health and Care Excellence (NICE) in the United Kingdom 
and endorsed by the American Joint Committee on Cancer.17
2 |  METHODS
This study was approved by the University of Cambridge 
Psychology Research Ethics Committee (PRE.2016.103). 
Participants gave informed consent before taking part.
The original interface allowed of parameters describ-
ing the patient and their cancer. The user could then select 
a combination of treatments that are available after surgery 
to further treat the cancer. These included hormone therapy, 
chemotherapy and trastuzumab (a targeted antibody treat-
ment). Other treatments are available but were not included 
in Predict: Breast Cancer at the time. After entering param-
eters and selecting treatments, the user was presented with 
predicted survival at 5 and 10 years in the form of text and a 
stacked bar chart. The display included a breakdown of how 
each treatment contributed to the estimated survival rate (see 
Figure 1).
2.1 | Background research
To understand more about patient use of Predict: Breast 
Cancer, the term 'Predict' was searched for on the fora of 
prominent breast cancer charities. There were not sufficient 
data for a detailed analysis although the comments found 
provided a valuable insight into patients' unmediated experi-
ence of the Predict: Breast Cancer website.
We conducted a focus group with members of the gen-
eral public. Women from the Cambridge area (n = 7, Mean 
age  =  46, SD  =  13) were recruited via online community 
message boards. Participants' education level spanned GCSE 
level (1), A level (2), degree level (3) and post- graduate (1). 
F I G U R E  1  The original interface as it appeared on the Predict: 
Breast Cancer website. Hovering over a segment would reveal a pop- 
up display showing the increase in survival. The increases were also 
displayed as text below the chart
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Household income categories spanned less than £10,000 per 
annum to £51,000 to £60,000 per annum. We sampled the 
general population to obtain the perspective of women en-
countering prognostic breast cancer information for the first 
time. Participants attended a session lasting 90 min that fol-
lowed a semi- structured agenda. Participants discussed their 
expectations of a prognostic website, how comprehensible 
different visualisations were, and features not currently avail-
able that they would find desirable. An audio recording of 
the focus group was made, and notes taken by the two re-
searchers were present. Notes and recordings were subse-
quently analysed for comments and suggestions that enabled 
us to produce high- level requirements for the design of a new 
interface.
To validate and expand our feedback, we also carried out 
an online survey (n  =  50, mean age  =  37, SD  =  10) with 
members of the public recruited from a national participant 
pool (prolific.co). Participants' household income spanned 
below £10,000 per annum to over £100,000 per annum. The 
modal income category (n  =  12) was £20,000– £30,000. 
Participants' education level spanned none (1) to doctoral 
(2). The modal education level was secondary/high school 
(22). Participants were given input parameters, asked to enter 
these into Predict: Breast Cancer and then comment on the 
appearance, perceived trustworthiness of the site and on 
how the results were displayed. The survey respondents also 
rated Predict: Breast Cancer on appearance, trustworthiness 
and interpretability of the outputs on a 5- point scale ranging 
from 'completely disagree' to 'completely agree'. Free- text 
responses to the online survey were aggregated and given 
an initial code to identify comments relating to a common 
theme. These were further summarised to produce broad de-
sign requirements.
To understand more about clinician use of the tool we 
observed a multi- disciplinary team meeting (MDT) at the 
Cambridge Breast Unit. MDTs were identified during the 
background research as a critical use case for Predict: Breast 
Cancer. During MDTs a team of clinicians collectively de-
cide on which adjuvant treatments to recommend to a patient, 
and Predict: Breast Cancer is often used to determine whether 
treatments offer enough benefit to merit being recommended. 
Notes from the observation of the MDT were reviewed to 
derive high- level design requirements specific to that setting.
We also held a focus group with 18 clinicians including 
11 breast oncologists (specialisms included radiotherapy and 
chemotherapy) at the Cambridge Breast Unit, addressing how 
they used the site, issues that they had with the current ver-
sion and their opinions on how it could be improved. The cli-
nician focus group was not recorded but was attended by four 
researchers whose meeting notes were collated and compared 
to identify issues within the remit of the interface redesign.
To validate our clinician feedback, we also surveyed at-
tendees at the UK Breast Cancer Group (UKBCG) meeting in 
November 2016. Respondents (n = 75) were from 44 institu-
tions across England, Scotland, Wales and Northern Ireland. 
All respondents indicated that they had used Predict: Breast 
Cancer before. The majority of respondents were consultants 
(47) but also included surgeons, research fellows and regis-
trars. The survey asked respondents about the contexts they 
used Predict: Breast Cancer in, and the devices they used to 
access it. Respondents could indicate features from other 
prognostic tools that they would like included and were also 
asked whether they agreed with a list of potential new pre-
dictors and outputs. Free- text fields were included to allow 
respondents to expand on any of their answers.
In all cases we adopted a qualitative descriptive ap-
proach18 which minimises interpretation by the researchers, 
instead focussing on recording and summarising participants' 
contributions. This is an efficient approach suitable for back-
ground research in UCD, where the objective is to generate a 
broad range of issues that should be considered when design-
ing a new interface.
2.2 | Iterative development
We developed prototypes informed by the background re-
search. Wireframes were used to encourage feedback that 
included substantial changes to the design. A wireframe is a 
sketched interface used to communicate potential functions 
and layouts. The sketched appearance avoids participants as-
suming the design has already been finalised and instead en-
courages them to suggest different layouts and features. Later 
iterations with increased functionality and realism resulted 
in incremental feedback until a final prototype was ready for 
launch.
Using wireframes we obtained feedback and sugges-
tions for improvement from breast cancer clinicians at 
Addenbrooke's hospital (6 oncologists). To broaden the 
feedback, we also visited clinicians at Hillingdon hospital 
(3 cancer nurse specialists and 2 oncologists). For both sites 
participants were shown the wireframes and given a demon-
stration of example interactions that it would allow (e.g., se-
lecting different timeframes over which to see the predictions 
of the algorithm). Participants were then invited to discuss 
problems, benefits and alternative solutions. These meetings 
were attended by at least 2 researchers and notes were col-
lated and compared to produce design requirements for the 
next iteration– – a functioning prototype.
Based on the wireframe feedback, a functioning prototype 
was made available to participants for usability evaluation. 
These included 7 breast oncologists who had indicated that 
they were willing to be contacted when we surveyed the UK 
Breast Cancer Group (UKBCG) 2016 conference, and 12 
breast cancer patients (mean age = 53, SD = 10) were re-
cruited from a pool of participants who had previously worked 
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with our centre. These patients had previously been diag-
nosed with breast cancer, but were beyond the stage where 
Predict: Breast Cancer is typically used. Patients' household 
income ranged from the £21,000 to £30,000 category to the 
over £91,000 category. Education levels spanned GCSE (1), 
A- level (2), degree (6) and post- graduate (3). Participants 
were asked to interact with the website whilst software re-
corded video, audio and mouse movements. Each participant 
undertook a pre- set task of entering data and interpreting the 
results, as well as some unstructured interaction in which 
they were asked to use the site as they would normally.
Notes and reviews of recordings were used to produce a 
table for each participant detailing issues encountered and 
their location within the website. User interface updates to 
address consistent issues were made on an ongoing basis 
such that later participants saw changes made as a result of 
earlier feedback.
In the final stage we employed a graphic designer to de-
velop a professional standard design for the website based on 
the participant feedback. This prototype was made available 
to the patient advocacy group Independent Cancer Patients' 
Voice, who reviewed the site before the final iteration and 
launch.
3 |  RESULTS
3.1 | Background research
Table 1 summarises the principal issues and design require-
ments identified from the background research with non- 
clinicians. These were derived by grouping forum comments 
and focus group notes into broad themes. The comments 
shown in Box 1 were chosen to be representative of recurring 
sentiments found on the breast cancer fora.
The public survey data resulted in 249 free- text comments. 
These were given an initial code, for example, the comments: 
'provides statistical info but fees very clinical, […]at a time 
when you are dealing with cancer you might appreciate a 
more personal feel'. and 'It may provide help and reassurance 
to see actual numbers. However I do think it's a little imper-
sonal - especially to a potentially vulnerable cancer sufferer' 
were initially coded as 'impersonal'. The impersonal code 
was further summarised along with similar codes to make up 
the 'Appearance too basic and impersonal' issue in Table 1. 
Participants' Likert ratings were largely positive about the 
site with the majority selecting a better than neutral rating for 
each of the questions (see Table S1 ).
After participants had entered the parameters we gave 
them, we asked them to report the predicted survival for 
women who: (1) have no adjuvant treatment, (2) have 
only hormone therapy and (3) have hormone therapy and 
chemotherapy. Ninety- two per cent answered question 1 
correctly, however only 58% and 46% got questions 2 and 
3 correct, respectively. Errors were due to participants re-
porting the increase in survival associated with a treatment 
rather than the total survival. These data point to a possible 
misinterpretation of the stacked bar charts such that each seg-
ment is viewed as an alternative treatment rather than being 
in addition to the segments below it (see Figure 1 for an ex-
ample of the display). We should acknowledge, however, that 
these errors could equally be a misinterpretation of the ques-
tion rather than the chart, although subsequent research does 
point to problems in interpreting the chart.19
From the three sources of non- clinician feedback, we de-
rived the following overarching themes.
Fear of a poor prognosis: Many participants indicated 
that they would be put off using a prognostic tool for fear 
of receiving worse news than they expected. For some, there 
was a sufficiently strong sense of foreboding that using the 
tool would simply be too frightening (e.g., Box 1 comment 
1).
Appearance and trustworthiness: Participants in the on-
line survey and focus group identified that the site appeared 
'clinical', 'cold' and 'basic'. The clinical tone resulted in a 
perceived lack of empathy for the user whilst the basic style 
risked a lack of authority. Focus group participants also in-
dicated that whilst icon arrays were a good communication 
device in general, the use of human- shaped icons would be 
too upsetting and that abstract representations were prefera-
ble. The site was perceived to be trustworthy though this was 
in large part because of its affiliation to the UK's National 
Health Service.
Scepticism about statistics and predictions: A common 
response was to question the accuracy of the predictions. 
This scepticism was a result of the perception that the tool 
did not ask for all the possible relevant information (e.g., ex-
ercise levels or type of surgery). Participants felt, therefore, 
that where their individual circumstances were not taken 
into account by the tool, this limited its ability to provide a 
useful prediction. A related response was the perception that 
percentages felt meaningless for an individual. Some partic-
ipants felt that applying a percentage chance to a categorical 
event (survival) was hard to understand (e.g., Box 1 comment 
4). Another important factor was that other tools appear to 
provide different estimates. This potentially has the effect of 
reducing trust in all tools, or leading patients to use those 
tools that they perceive to provide more optimistic outlooks 
(e.g., Box 1 comment 3)1. Finally, participants felt that the 
predictions must be based on old data, and therefore that they 
would not be up to date and include recent developments in 
treatment (e.g., Box 1 comment 2).
Information on side effects: Participants identified that 
the tool only supplied quantitative information about the ben-
efits of adjuvant therapies, and that they would also want to 
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know about the side effects and their likelihood. Participants 
felt that in some cases side effects might be severe enough 
that they would refuse a treatment with only a small benefit. 
Of particular note was that some patients in the forum indi-
cated surprise at how little potential benefit they were receiv-
ing from their treatment regimens (e.g., Box 1 comment 5).
Interface: Several aspects of the existing interface were 
problematic for participants. The primary concern was that 
small increments were difficult to read on the bar chart (see 
Figure 1). Many participants in the online survey also stated 
that the wording 'an extra x women would survive with (treat-
ment)', confusing and would prefer the total number surviv-
ing instead.
Table 2 shows the key issues identified from the clinical 
feedback along with their source. The UKBCG data indicated 
a majority support for all but two predictors in Predict: Breast 
Cancer (exercise level and smoking status, see Table S4 for 
full data). A majority of the respondents supported the intro-
duction of all of the proposed new outputs (Table S5). Survey 
responses also indicated a wide range of devices were used 
to access Predict: Breast Cancer, and that it was used in a 
variety of contexts (full data in Tables S2 and S3). The most 
common of these was in consultation with patients (80% of 
respondents), but alone (71%) and MDTs (50%) were also 
frequent responses. Participants were also able to indicate 
(via free- text response) which features of other tools they 
T A B L E  1  Major design requirements derived from background research with patients and the public
Source Issue Requirements
Patient fora Fear of poor prognosis Address language, appearance and provide 
links to support
Other tools provide different predictions Guidance on interpreting prognostic statistics
Averages not perceived as relevant to 
individuals
Guidance on interpreting prognostic statistics
Predictions must be based on old data to 
provide long term predictions
Guidance on interpreting prognostic statistics. 
FAQ section.
Treatment benefit sometimes perceived to be 
surprisingly small
Ability to trade- off benefits and adverse 
effects
Public survey n = 50, mean age = 37, 
SD = 10
Appearance too basic and impersonal Address language, appearance and provide 
links to support
NHS critical to instilling trust More prominence to NHS branding
Want more information about side effects Ability to trade- off benefits and adverse 
effects
Outputs difficult to read/interpret Improved visualisation of results
Averages not perceived as relevant to 
individuals
Guidance on interpreting prognostic stats
Public focus group n = 7, mean age = 46, 
SD = 13
Fear of poor prognosis Address language, appearance and link to 
support
Desire to take part in decision- making Facilitate communication between patients 
and clinicians
Technical information important but 
incomprehensible
Rewrite technical information to improve 
comprehension
Preference for abstract visualisations. Icons 
representing people too upsetting
Consider emotional impact in design of 
graphics and labelling
Want information on side effects Ability to trade- off benefits and harms
BOX 1 Illustrative comments about the 
Predict: Breast Cancer tool on patient forums. 
Note comments are paraphrased to preserve the 
original posters' anonymity.
1. Why would anyone want to know predicted sur-
vival rate? Living through this is bad enough.
2. All these tools are based on outdated figures any-
way. Someone diagnosed today is likely to do better 
than someone diagnosed 10 or 15 years ago.
3. I like the CancerMath tool because it gives much 
more optimistic chances (Common comment, but 
N.B. this is because it does not include non- breast 
cancer mortality).
4. It will come back or it won't, percentages don't 
make sense.
5. The benefit of the treatment was so small, very 
surprised.
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would like to see included. The features mentioned at least 
three times were: disease- free survival (3), outputs to share 
with patients (3), mobile- friendly interface (3), cancer recur-
rence information (9), cancer- specific mortality (9) and co- 
morbidities (20).
The UKBCG survey data provided good validation of the 
clinician focus group feedback. The proposed new outputs all 
received support, as did the majority of proposed predictors. 
The free- text responses also raised similar issues, including 
technical IT requirements, sharing of outputs with patients 
and the value of recurrence forecasts.
The following themes identify and expand on commonal-
ities identified in Table 2:
Simplicity: Clinicians were very keen that the tool 
should be quick to use and with minimal constraints on 
access. This included highlighting technical restrictions 
in hospitals such as poor WiFi coverage and outdated 
browsers. Feedback also emphasised that the site should 
not require users to log in or demand inputs that might not 
be available. 'Keep it simple' was a sentiment expressed 
in the focus group and survey comments (there were four 
unsolicited comments to this effect in the survey), and 
simplicity was a much appreciated feature of the original 
interface.
Additional functionality: Many clinicians were keen 
to see new treatments added to the prognostic model (e.g., 
radiotherapy and bisphosphonates, see also Table  S4). 
Clinicians also highlighted additional outputs that would be 
useful such as different time frames for the model's predic-
tions. Clinicians also reported that not all patients would have 
access to computers and internet, meaning the ability to print 
the outputs was particularly useful.
Different use cases: Observation of the MDT and feed-
back from clinicians highlighted the variety of contexts in 
which the tool is used. In MDTs the tool was most often used 
in cases whether it was unclear if a sufficiently large increase 
in survival would be obtained. Consequently, the ability to 
inspect small increments in the tool's output was critical. 
Clinicians also used the tool with patients during consulta-
tions to help explain the benefits of treatments. Additional 
uses identified from the survey included research, teaching 
and meeting preparation.
3.2 | Interface development
The new Predict: Breast Cancer website can be visited at 
the following address: https://breast.predi ct.nhs.uk/ and the 
open- source code is available here: https://github.com/Winto 
nCent re/predi ct- v21- main
Clinician feedback on the wireframe prototype was used 
to confirm or reject different features that we proposed in re-
sponse to the background research. In addition, new issues 
were identified that were implemented in the next iteration 
where this was possible. Where it was not possible to imple-
ment requested features, they were recorded for future imple-
mentation. Table S6 in the Supplementary Materials outlines 
the assessment of the various features in more detail.
A fully functioning online prototype was built that incorpo-
rated the features approved, or identified for implementation, 
T A B L E  2  Major design requirements derived from background research with clinicians
Issue Source Requirements
Time per patient typically around 3 min MDT observation Ability to generate results quickly
Importance of not carrying over parameters 
from previous patient
MDT observation Ability to reset interface
Site is most useful when predicted increase in 
survival is small (3%– 5%)
MDT observation Ability to inspect small increments with 
precision
New predictors requested Clinician survey (Table S4); Clinician focus 
group
Implement new predictors or add to future 
research programme
New outputs requested Clinician survey (Table S5); Clinician focus 
group
Implement new outputs or add to future 
research programme
Keep interface simple Clinician survey Maximise speed and ease of use
Variety of different use cases (e.g., teaching, 
patient consultations and MDTs)
Clinician survey; Clinician focus group Create outputs and visualisations to support 
each use
Unusual technical requirements in some 
hospitals
Clinician focus group Ensure backward compatibility with browsers 
no longer supported by manufacturer, and 
enable offline use
Patients may not have ability to access online 
tools
Clinician focus group Print function (with graphics being clear in 
grey scale)
Clinician survey: 75 respondents at the UK Breast Cancer Group Meeting 2016. Clinician focus group: 18 clinicians at the Cambridge breast unit. See methods for 
further details.
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in the feedback on the wireframe interfaces. The function-
ing prototype was then submitted to usability testing. The 
analysis of usability testing data with patients and clinicians 
revealed two broad categories of issue. The first was confu-
sion over the subtler functionality of the interface, such as 
not realising that that the information icons were clickable or 
failing to notice a button.
The second category concerned how the patients' personal 
circumstances would map on to the input fields available on 
the site. For instance, participants wanted to know why the 
interface does not differentiate between the types of surgery a 
patient can have (e.g., lumpectomy or mastectomy), or what 
to do when they lacked sufficient information to fill in all the 
input fields.
As issues were identified they were addressed through 
changes to the interface. These were predominantly adding 
more explanatory information text, and alterations to the 
layout and prominence of interactive elements. Figures  2 
and 3 shows the display incorporating these changes. See 
Supplementary Materials, for example, data on the issues 
raised during usability testing and their solutions (Table S7).
Our approach to conflicting feedback was to try and ac-
commodate both points of view through compromise. For 
example, we received mixed feedback about the use of uncer-
tainty ranges. These were included but turned off by default 
so as to not overwhelm users who might find them difficult 
to interpret. Although led by feedback from users, final deci-
sions about the interface were made by the authors.
With respect to the default settings of the interface, based 
on participant feedback, we erred on the side of the simplest 
presentation possible. For instance, with the decimal places 
on predictions, by default the interface presents a whole num-
ber, but interested users can press a button to see more pre-
cise values. We also added flexibility to the default settings 
such that users can open a settings menu and choose which of 
the presentation formats they want the display to default to. 
This menu also allows Bisphosphonates to be removed from 
the treatment options, as it is not available in all geographic 
regions.
3.2.1 | New features
The finished interface includes many new features derived 
from the background research and feedback during iterative 
development process. These include: The option to choose a 
preferred method for displaying the results (Figure 2A), the 
inclusion of non- breast cancer mortality (Figure 2B), click-
able information icons which display explanations of input 
fields and outputs (Figure 2C), the ability to specify the time 
range over which to display the predictions (Figure 2D) and 
the optional provision of precision estimates around the pre-
dictions (Figure 2E).
The research and design process also revealed addi-
tional predictors and treatments that patients and clini-
cians would like to see as part of the model. Data were 
available for some of these, consequently bisphospho-
nates and extended hormone therapy have been added 
as treatments, whilst menopausal status has been added 
as a predictor. The Predict: Breast Cancer site now also 
has updated FAQs and technical information pages for 
non- experts. The site has been translated into Spanish, 
French, Portuguese and Chinese, and a graphic designer 
was employed to create a coherent professional appear-
ance for the site.
3.2.2 | Future features
The design process allowed us to identify additional predic-
tors and outputs that clinicians and their patients would find 
useful. These data provide a valuable insight into how users 
would like the site to evolve, and they form the basis for a 
plan of future research and development. Crucially, these de-
velopment plans are user- driven and reflect how patients and 
clinicians would like the algorithm and interface to work in 
order to be maximally useful.
One requested function was the ability to use the tool for 
estimating the impact on survival of stopping adjuvant treat-
ments. Patients may request this information because the side 
effects of treatments are often unpleasant enough that they 
want to re- assess whether the treatments are worth continu-
ing with.
A common query amongst patients was how to gauge 
the likelihood and severity of side effects. Whilst qualitative 
information on side effects is available, there is very little 
quantitative information. Work is now underway to provide 
these data.
A related issue is the increase in mortality that some 
treatments cause. This can, in some patients, outweigh any 
benefit, meaning the treatment would result in a drop in pre-
dicted survival rates. This vitally important component is not 
currently included in Predict: Breast Cancer, and research is 
underway to determine how best to display such a 'negative 
benefit' unambiguously in each of the graphical formats used 
in Predict: Breast Cancer.
Two frequently requested features were co- morbidities as 
a patient input, and radiotherapy as a treatment option. The 
data are not currently available to model the effects of co- 
morbidities. However, radiotherapy as a treatment option is 
being modelled and will be added to a future release of the 
site.
Finally, both clinicians and patients expressed the desire 
to see the chances of breast cancer recurrence as well as sur-
vival. This can be modelled, and a programme of work is 
underway on how best to visualise this.
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4 |  DISCUSSION
Our background research revealed a number of themes which 
we addressed in the design of a new interface for Predict: 
Breast Cancer. For our non- clinician participants these in-
cluded: Fear of a poor prognosis, appearance and trustworthi-
ness, scepticism about statistics, information on side effects 
and problems with the interface. The background research 
with clinicians revealed a desire for simplicity, additional 
functionality and the need to cater for several different use 
cases. These themes reflect the differing needs of patients 
and clinicians. For patients, they reflect the fact they are 
dealing with new information that is difficult is to absorb, 
both in terms of its emotional impact and its complexity. The 
clinician group was more expert and, therefore, interested in 
increased functionality and flexibility, as long as this this did 
not come at the cost of speed and simplicity. In this particu-
lar case, simplicity centred on not obstructing use of the tool 
by requiring logins, mandatory input fields or recent browser 
technology. As with simplicity, catering for different con-
texts of use is a fundamental principle of UCD12,20 but can 
be easily overlooked.
The broad requirements identified in the background re-
search resulted in initial prototypes that were iteratively re-
fined with feedback from clinicians and patients. Usability 
testing then made sure that our proposed solutions were ef-
fective and usable. The end result was the new interface to 
Predict: Breast Cancer which is now live.
During this research, we identified some key recommen-
dations for developing public or clinician- facing prognostic 
algorithms (see Box 2). The first of these is to make interac-
tions flexible (R1). This means not prescribing to users how 
F I G U R E  2  Display options for 
the new Predict: Breast Cancer website 
showing a survival curve in the top panel 
and a tabular format in the bottom panel. 
Users can choose from these formats and 
three others. (A) choice of display, (B) 
survival rate excluding breast cancer, (C) 
information icons, (D) choice of timeframe 
and (E) optional prediction ranges. Figure 3 
shows the other three display options
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they should use the tool, instead building in enough flexibil-
ity so that different users can interact in different ways. For 
the new Predict: Breast Cancer interface we tested features 
that would allow a side by side comparison of treatments. 
Ultimately, however, users preferred to change the parameters 
and observe how the displays changed. Rather than prescribe 
how users should compare treatments we made the displays 
responsive so that they updated immediately upon a change 
to the predictors or treatments.
A further example of this approach was our inclusion of 
multiple ways of displaying the results, thereby allowing the 
user to select whichever format best suited their purposes. 
F I G U R E  3  Three different display 
options for the new Predict: Breast Cancer 
website. The top panel shows a stacked bar 
chart, the middle panel a text representation 
of the same results and the bottom panel 
shows an icon array. Users can choose of 
which these displays they want to use to see 
the results. The two other display options 
are shown in Figure 2
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Whereas tables facilitate MDT inspection of small incre-
ments, survival curves allow patients in consultations to see 
the how the benefits of treatments change over time. We also 
found that users liked being able to compare different for-
mats as a means of checking their comprehension. The use of 
multiple presentation formats has previously been identified 
as beneficial for patient understanding in a review of the lit-
erature on prognosis communication.21
Our second recommendation, to put statistics in context 
(R2) is implemented in our inclusion of the survival rates 
for women who do not die of breast cancer. This information 
provides critical context by putting an upper bound on the 
possible benefit of a treatment. A survival probability of 60% 
may seem less frightening in the context of a survival prob-
ability of 70% for women who do not die of breast cancer. 
And the maximum possible increase of 10% provides con-
text in evaluating the efficacy of a treatment that improves 
survival by 5%. Other information, such as uncertainty es-
timates, allow the tool to convey not just the point estimate 
for survival (e.g., 60%) but also a range indicating the likely 
variability around the estimate, (e.g., 57%– 63%), especially 
important to consider when the potential benefits are small.
The provision of context has wide support in the liter-
ature on risk communication and is a key recommenda-
tion in the recently updated International Patient Decision 
Aid Standard (IPDAS)22 as well as in a number of reviews 
on risk communication.13,23 A key concept here is that of 
evaluability24 which relates to whether a person can assess 
the information as good or bad, and therefore whether it is 
useful to decision- making. Changing the evaluability of in-
formation has been shown to lead to preference reversals, 
including medical contexts.25 Unfamiliar medical informa-
tion may be especially difficult to evaluate for patients, and 
hence the importance of contextualising such information. 
The use of uncertainty ranges on estimates was regarded 
as beneficial for clinicians, and whilst some patients were 
interested, it should be noted that they can be difficult to 
interpret for non- specialists.22
The recommendation to address gaps in knowledge (R3) 
is about ensuring the predictors are entered correctly and the 
users (both clinicians and patients) have confidence in the 
resulting predictions. Our background research and usabil-
ity testing identified instances of both clinicians and patients 
being unsure of what was being asked of them. This is an 
issue that has previously been identified in the context of 
prognostic models, where the applicability of a tool can be 
limited through ambiguity in what is being asked for in a pre-
dictor.26 In addition to ensuring predictors are entered accu-
rately, previous research has also identified that clarity about 
how the algorithm functions is important in increasing users' 
confidence in the results.27 In our interface this was in part 
achieved by adding FAQ and technical information sections 
to the website that used lay language where possible. The in-
terface also includes information buttons that when selected 
launch a pop- up window providing a detailed explanation of 
the predictor being requested or the output being presented.
In our research it quickly became apparent that users 
would want to evaluate any increase in survival against the 
potential for side effects. Our recommendation to provide 
BOX 2 Recommendations for communicating 
with prognostic models
The following recommendations have been derived 
from our experience of developing the new Predict: 
Breast Cancer interface. Each is addressed in more 
detail in the discussion.
R1. Make interactions flexible: It is important for 
an interface to allow the user to interact with the 
model's predictions in a way that suits their needs. 
Rather than restrict or prescribe how the user should 
behave, try to build in flexibility. This maximises the 
chances of catering to different use cases.
R2. Put statistics in context: It is possible to com-
municate numbers perfectly accurately but leave the 
recipient none the wiser. The provision of contex-
tual information can be critical in turning a number 
into information. Many users, especially patients, 
need a frame of reference to meaningfully evaluate 
a prediction.
R3. Identify and address gaps in knowledge: It is 
important to address potential misunderstandings 
explicitly. For patients and clinicians, supporting in-
formation helps ensure the data is input correctly and 
therefore increases confidence in the results.
R4. Provide the downsides: People want to under-
stand the negatives as well as the positives. When 
using models to provide the benefits of treatments, 
consider that many patients will want to be able to 
trade- off that information with the likelihood and se-
verity of side- effects.
R5. Generate a programme of research: During 
background research and user testing of a prognostic 
model, many new predictors and potential outputs 
will be suggested. Where these cannot be imple-
mented (due to lack of data, for example) they should 
nonetheless be recorded as they provide a valuable 
source of user- driven future research projects.
R6. Engage with prospective users: The most impor-
tant recommendation is to obtain as much feedback 
from the target audience as possible. Each prognos-
tic model will be unique, and user centred design re-
veals vital requirements that are often unforeseeable 
without consulting users.
   | 11FARMER Et Al.
the downsides (R4) is not something we could immediately 
implement in Predict: Breast Cancer as quantitative data 
on the probability and severity of side effects is not readily 
available. Nonetheless developers of other models should in-
vestigate whether such information is available in their do-
mains. This theme relates to Recommendation 2 in that it is 
of course difficult to evaluate a treatment if only the benefits 
are presented. The desire amongst patients for information on 
negative effects is also supported in the literature on progno-
sis communication.21 It may be that patients would prefer not 
to have treatment with a small average reduction in mortality 
if it means substantially lowering quality of life. For those 
who take treatment, awareness of the likelihood and severity 
of potential side effects (and ways to ameliorate them) could 
help increase adherence to the treatment and reduce worry 
about symptoms that arise.
The research to provide quantitative data on the side ef-
fects of treatments shown in Predict: Breast Cancer is un-
derway, and provides the basis for our recommendation to 
Generate a programme of research (R5). Many more sug-
gestions for predictors and features in Predict: Breast Cancer 
were made than we could implement. However, these sug-
gestions remain a valuable record of what users would like 
to have access to. For popular requests that cannot be met, 
perhaps due to a lack of data, researchers have a ready- made 
project with excellent chances of impact.
The last, and most important, recommendation is to 
Engage with prospective users (R6). This is fundamental to 
maximising the impact that a model can have. However, sta-
tistically sound and accurate a model is, if it cannot be used 
by its intended audience, or lacks some critical feature, it will 
not achieve the impact it otherwise could.
Engaging with users at all stages of the design will 
identify issues that cannot be foreseen. For Predict: Breast 
Cancer we had to conduct the background research in order 
to understand the different contexts of use and critical 
technical requirements for the site to continue working on 
hospital IT systems. We also did not foresee that, although 
recommended in the risk communication literature,13,28,29 
icon arrays would be deemed to be distressingly morbid 
when human- shaped. More generally, the need for research 
on side effects, the extent of the supporting information re-
quired by users and the new predictors and outputs, were all 
based on feedback from prospective users. These features 
and outputs would likely have been missed or underesti-
mated without their input. An equally important aspect of 
UCD is determining what does not work– – without it, we 
would certainly have included features that were either not 
used, or worse, misunderstood.
Consulting with users is increasingly recognised as an 
important step and is an overarching principle in the IPDAS 
recommendations for communicating probabilities to pa-
tients.22 The full UCD process extends this idea to the whole 
interface. UCD is comprised of many more techniques and 
methods than we employed in the development of the in-
terface for Predict: Breast Cancer. Which methods are used 
will depend on the target audience, resources available and 
the expertise of the researchers involved. However, the fun-
damental process of UCD is straightforward: Engage in 
background research, then iteratively test and refine designs 
with the target audience. Even if resources are very limited, 
there is still value in engaging in the process to whatever 
extent is possible.
The new Predict: Breast Cancer website is live and de-
livering thousands of sessions worldwide per week. Its de-
velopment was based on a combination of broad background 
research and user- testing with the target audiences. By involv-
ing users in the design process, we believe it has enhanced the 
potential for shared decision- making and informed consent. 
Furthermore, the interface has now been successfully applied 
to a similar prognostic algorithm for prostate cancer (https://
prost ate.predi ct.nhs.uk) where its effects on decision- making 
and patient satisfaction are being evaluated in clinic.30,31
4.1 | Study limitations
To ensure the effectiveness of design decisions there is no 
substitute for feedback from prospective users in the devel-
opment process. The extent to which this is possible will 
vary from case to case. Ideally, in our case, this would have 
involved working with patients who were in the process of 
making decisions about adjuvant treatments in all stages of 
the interface development. We were only able to recruit a 
limited number of patients and we deemed the usability test-
ing the most valuable time to involve them. Our background 
research would have been improved by a greater involvement 
of patients. Although our participants recruited from the gen-
eral public gave us useful insights into how Predict: Breast 
Cancer is perceived by a first time user, they were not hav-
ing to process the information with the distress caused by a 
recent cancer diagnosis.
4.2 | Clinical implications
Epidemiological models can provide vital information for 
clinicians and patients deciding on which treatments to take. 
This in turn can lead to increased survival rates and all- round 
improved decision- making. UCD can remove the barriers to 
these benefits and, by engaging with patients, set an agenda 
for future development that really addresses their needs. In 
the case of Predict: Breast Cancer this has led to the first 
quantitative review of side effects for many adjuvant thera-
pies and additional modelling to address the requested addi-
tional treatments and outputs.
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4.3 | Conclusions
Prognostic algorithms have great potential for improv-
ing shared decision- making and informed consent. If made 
available in clinic, they can ensure that patients and health-
care professionals receive accurate and relevant information 
about the personalised benefits and harms of different treat-
ment options. In order to make such complex and emotion-
ally difficult information available in a clear, unambiguous 
and sensitive manner, UCD is critical. Algorithms need to 
be statistically validated, but must also be easy to use, trust-
worthy and produce outputs that are clear and useful to their 
users.
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ENDNOTE
 1 Major discrepancies were due to some tools excluding mortality not 
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